Articles

Poll

Podcasts

Slideshows

Videos

Nephrology

The HCPLive nephrology page is a resource for medical news and expert insights on kidney disease. This page features expert-led coverage, articles, videos and research on the therapies and development of treatments in nephrology, and more.

Mohamad Hussain, MD, PhD, discusses Phase 3 findings on Humacyte's bioengineered vessel and its potential role in vascular access for women on dialysis.

Bioengineered Vessel Increases Catheter-Free Time in Women on Dialysis

Matthew Breeggemann, MD, of UCSF discusses genetic testing, risk stratification, and the future of personalized CKD management in 2026.

Rethinking CKD: AKI's Long-Term Impact and the Push for Earlier Intervention

Nephrology in July 2026: FDA approvals for atacicept, iptacopan, and Furoscix in IgAN/CKD, plus new IgAN and CKD trial data.

8 Nephrology Headlines You Missed in July 2026

The IL-6 inhibitor missed its primary MACE endpoint in ASCVD, CKD, and inflammation despite expected biological effect on target engagement.

Ziltivekimab Fails to Reduce MACE Risk in Phase 3 ZEUS Trial

Nephrology experts discuss how CKD care has evolved in 2026, including SGLT2 inhibitors, finerenone, GLP-1 receptor agonists, and personalized treatment.

Where Are We Now? Treating Chronic Kidney Disease in 2026

Hunter Champion, MD, PhD, covers his experience with furosemide injections in reducing hospital readmissions and how the ReadyFlow may decrease them further.

Furoscix ReadyFlow (Furosemide) and its Impact on HF, CKD Edema Treatment

The approval makes MannKind Corporation’s furosemide injection the first and only autoinjector delivering SC furosemide with IV-equivalent exposure.

FDA Approves Furosemide Injection (Furoscix ReadyFlow) for Edema in HF, CKD

Marc Richards, MD, discusses how new therapies and combination treatment strategies are transforming evidence-based care for chronic kidney disease.


Expanding Era of Evidence-Based CKD Care, With Marc Richards, MD

Michael Richards, MD, discusses aldosterone's role in CKD pathophysiology and why targeting this pathway may reshape kidney disease treatment.

Why Aldosterone Has Become a Key Target in CKD Care, With Marc Richards, MD

NYU Langone’s Conor Donnelly, Allan Massie, and Michal Mankowski explain why follow-up after kidney transplant referral is critical to improving access.